Last reviewed · How we verify

alogliptin + pioglitazone — Competitive Intelligence Brief

alogliptin + pioglitazone (alogliptin + pioglitazone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + thiazolidinedione. Area: Diabetes.

marketed DPP-4 inhibitor + thiazolidinedione DPP-4 and PPAR-γ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

alogliptin + pioglitazone (alogliptin + pioglitazone) — Kun-Ho Yoon. Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
alogliptin + pioglitazone TARGET alogliptin + pioglitazone Kun-Ho Yoon marketed DPP-4 inhibitor + thiazolidinedione DPP-4 and PPAR-γ
Teneli / Teneli + pio Teneli / Teneli + pio Tanabe Pharma Corporation phase 3 DPP-4 inhibitor; combination: DPP-4 inhibitor + thiazolidinedione DPP-4 (dipeptidyl peptidase-4); pioglitazone targets PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + thiazolidinedione class)

  1. Kun-Ho Yoon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alogliptin + pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/alogliptin-pioglitazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: